Teva adds 790 Croatians to layoff toll

Generics may hold diversification promise for Big Pharma, but that doesn't mean generics companies are immune to the industry-wide cost-cutting imperative. Witness Teva Pharmaceutical Industries, the world's biggest maker of copycat meds. Yesterday we reported that Teva would shutter a Florida plant, laying off 300 in the process. Teva acquired the plant in Doral when it bought Ivax in 2006. 

And now there's more: The company also will cut 790 workers in Croatia. Those employees moved to Teva when the Israeli company bought Barr Pharmaceuticals, and along with it the Croatian unit Pliva, two months ago. Already Teva is streamlining Pliva in an attempt to boost its profitability in line with the company average. The layoffs amount to more than one-quarter of the unit's workers.

But Teva doesn't plan to stop at cost-cutting; it's plotting to take up slack manufacturing capacity at Pliva to make APIs and tablet drugs. The company aims to boost production there by 30 percent.

- read the story from Haaretz

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.